Risk-factors associated with extremely high cardiovascular risk of mid- and long-term mortality following myocardial infarction: Analysis of the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) registry
Krzysztof Dyrbuś,Mariusz Gąsior,Piotr Desperak,Przemysław Trzeciak,Jolanta Nowak,Peter E. Penson,Tadeusz Osadnik,Maciej Banach +7 more
Reads0
Chats0
TLDR
In this article, the authors identify subgroups of patients at the highest risk of death following myocardial infarction (MI) that might be considered as extremely high CVD risk.About:
This article is published in Atherosclerosis.The article was published on 2021-08-13 and is currently open access. It has received 12 citations till now. The article focuses on the topics: Myocardial infarction & Coronary artery disease.read more
Citations
More filters
Journal ArticleDOI
Step‐by‐step diagnosis and management of the nocebo/drucebo effect in statin‐associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP)
David Marais,Zeljko Reiner,Matteo Pirro,Manfredi Rizzo,Alexandros Sachinidis,Dan Gaita,Mohsen Mazidi,Daniel Pella,G.B. John Mancini,Stephan von Haehling,Maciej Banach,Julio Acosta,Mutaz Alkhnifsawi,Fahad Alnouri,Fahma Amar,Atanas G. Atanasov,G. Bajraktari,Sonu Bhaskar,Ibadete Bytyçi,Bojko Bjelakovic,Eric Bruckert,Alberto Cafferata,Richard Ceska,Arrigo F G Cicero,Xavier Collet,Magdalena Daccord,Olivier S. Descamps,Dragan Djuric,Ronen Durst,Marat V. Ezhov,Zlatko Fras,Adrian V. Hernandez,Steven P. Jones,Jacek Jerzy Jozwiak,N. Kakauridze,A. Kallel,Niki Katsiki,Amit Khera,Karam Kostner,Raimondas Kubilius,Gustavs Latkovskis,A. David Marais,Seth S. Martin,Julio A. Martínez,Dimitri P. Mikhailidis,Erkin M. Mirrakhimov,André R. Miserez,Olena Mitchenko,N.P. Mitkovskaya,Patrick M. Moriarty,Seyed Mohammad Nabavi,Devaki Nair,Demosthenes B. Panagiotakos,György Paragh,Peter E. Penson,Zaneta Petrulioniene,Arman Postadzhiyan,Raman Puri,Ashraf Reda,Dina Radenkovic,Michael Robert Rakowski,Jemaa Riadh,Dimitri Richter,Massimiliano Ruscica,Amirhossein Sahebkar,Naveed Sattar,Maria-Corina Serban,Abdullah Shehab,Aleksandr B Shek,Cesare R. Sirtori,Claudia Stefanutti,Tomasz Tomasik,Peter P. Toth,Margus Viigimaa,Pedro Valdivielso,Dragos Vinereanu,Branislav Vohnout,Michal Vrablík,Nathan D. Wong,Hung-I Yeh,Ji Zhisheng,Andreas Zirlik +81 more
TL;DR: A step‐by‐step patient‐centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long‐term compliance with lipid‐lowering therapy is presented.
Journal ArticleDOI
Which patients at risk of cardiovascular disease might benefit the most from inclisiran? Polish experts’ opinion. The compromise between EBM and possibilities in healthcare
Maciej Banach,Jarosław Kaźmierczak,P. Mitkowski,Krystian Wita,Marlena Broncel,Mariusz Gąsior,Marek Gierlotka,R.G. Gil,Piotr Jankowski,Maciej Niewada,Adam Witkowski +10 more
TL;DR: The fastest way to have inclisiran available for the polish patients, with the necessary changes of the existing drug program for PCSK9 inhibitors (B-101), is indicated, explaining why it is the optimal way, and why, taking into account available EBM data (the ORION program), inclisIRan should be added to this program.
Journal ArticleDOI
Extreme cardiovascular risk-do we need a new risk category?
Journal ArticleDOI
Challenges and Opportunities on Lipid Metabolism Disorders Diagnosis and Therapy: Novel Insights and Future Perspective.
TL;DR: Dyslipidemia has been globally recognized, for almost seven decades, as one of the most important risk factors for the development and complications of atherosclerotic cardiovascular disease (ASCVD) as mentioned in this paper.
Journal ArticleDOI
Is the standardized phase angle a predictor of short- and long-term adverse cardiovascular events in patients with acute myocardial infarction? A cohort study.
Sandra Azevedo Queiroz,Maria Cristina Gonzalez,Alana Monteiro Bispo da Silva,Jálissa Karla de Araújo Costa,Carlos Diego Ramos de Oliveira,Iasmin Matias de Sousa,Ana Paula Trussardi Fayh +6 more
TL;DR: In this paper , the phase angle (PhA) has been measured by bioelectrical impedance analysis (BIA) to identify the quality of the cell membrane and the distribution of body fluids.
References
More filters
Journal ArticleDOI
Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis.
Agata Bielecka-Dabrowa,Agata Bielecka-Dabrowa,Ibadete Bytyçi,Stephan von Haehling,Stefan D. Anker,Jacek Jerzy Jozwiak,Jacek Rysz,Adrian V. Hernandez,Adrian V. Hernandez,Gani Bajraktari,Dimitri P. Mikhalidis,Maciej Banach,Maciej Banach +12 more
TL;DR: In conclusion, statins may have a beneficial effect on CV outcomes irrespective of HF etiology and LVEF level, and Lipophilic statins seem to be much more favorable for patients with heart failure.
Journal ArticleDOI
The prevalence and management of familial hypercholesterolemia in patients with acute coronary syndrome in the Polish tertiary centre: Results from the TERCET registry with 19,781 individuals
TL;DR: The prevalence of FH according to the DLCN criteria in the Polish very high-risk population is significantly higher in patients with ACS than in patientsWith sCAD, and FH is a cause of increased all-cause mortality in the long-term follow-up.
Journal ArticleDOI
The year in cardiology 2018: prevention.
TL;DR: This paper presents a poster presented at the 2016 European Congress of Cardiovascular Research (ECR) entitled “Cardiovascular Research: Foundations of Cardiology and Hypothesis” (“Cardiology and its Foundations”).
Journal ArticleDOI
Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!
TL;DR: The issue of whether to start a discussion on treating all patients with T2DM as those at very high cardiovascular risk, or to at least to try to unify the definition and find such variables/risk factors which are easy to measure to help physicians to treat those patients optimally is raised.
Journal ArticleDOI
Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry.
TL;DR: The TERCET registry will allow unveiling real lipid profiles of the high‐ and very‐high risk patients treated in the tertiary hospital, and the results may play an essential role in establishing the patients' future clinical outcomes and help to assess if the lipid lowering therapy modifications changed the occurrence of CV endpoints.